SUMMARY:
House Bill 60 amends the Insurance Company Law concerning pharmaceutical coverage for oral anticancer medications. It would take effect immediately.

ANALYSIS:
House Bill 60 would pertain to insurance policies that provide pharmaceutical coverage for cancer chemotherapy or anticancer medications which have been approved by the United States Food and Drug Administration for general use in the treatment of cancer. Such policies would not be permitted to refuse coverage or impose cost sharing for orally administered anticancer medications on a less favorable basis than the coverage it provides or cost sharing it imposes for intravenously administered or injected cancer medications. Additionally, a health insurance policy may not comply with this requirement by imposing an increase in cost sharing solely for orally administered, intravenously administered or injected cancer medications. However, would be allowed to require prior authorization before orally administered anticancer medication is dispensed to a patient. This restriction would apply to insurance policies, subscriber contracts or certificates issued or entered into or renewed on or after the effective date of this legislation.

FISCAL IMPACT:
Enactment of this legislation will have no adverse impact on Commonwealth funds.

PREPARED BY: Jeff Miller
House Appropriations Committee (R)

DATE: February 24, 2015

Estimates are calculated using the best information available. Actual costs and revenue impact incurred may vary from estimates.